Press Releases

GAAP revenues of $331 million and non-GAAP revenues of $332 million GAAP net income per diluted share of $0.20 Non-GAAP net income per diluted share of $0.84 Second quarter results reflect an impact from the previously disclosed ransomware incident;...

GAAP revenues of $331 million and non-GAAP revenues of $332 million GAAP net income per diluted share of $0.20 Non-GAAP net income per diluted share of $0.84 Second quarter results reflect an impact from the previously disclosed ransomware incident;...

Omnicell, Inc. (Nasdaq :OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the second quarter 2022, after market on Thursday, August 4, 2022....

GAAP and non-GAAP revenues of $319 million GAAP net income per diluted share of $0.17 Non-GAAP net income per diluted share of $0.83 Launched innovative IVX Station robotic compounding technology Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,”...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the first quarter 2022, after market on Thursday, April 28, 2022....

New Technology and Enhancements to Intelligent Infrastructure Designed to Support Safer, Smarter Pharmacy Care Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and adherence tools for health systems and pharmacies, today...

Omnicell Intends to Nominate Mary Garrett for Election to Board of Directors at 2022 Annual Meeting of Stockholders Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management solutions and adherence tools for health systems and...

Combination of cloud-based technology, 340B program management, and EnlivenHealth® patient engagement solutions will drive key initiatives for Texas-based health system Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and...

2021 Total Product Bookings of $1.217 billion Full Year 2021 Revenues of $1.132 billion Ended Year with 151 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems Entered 2022 with Product Backlog of $1.254 billion Omnicell, Inc....

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the fourth quarter and full-year 2021, after market on Monday,...

Strategic acquisition of pharmacy technology solutions provider expands and deepens EnlivenHealth division’s footprint across key pharmacy segments Accelerates Software-as-a-Service (“SaaS”) technology roadmap Omnicell, Inc. (Nasdaq:OMCL), a leading...

Addition of specialty pharmacy management services expands Advanced Services portfolio to support access to and management of complex medications Expected to be accretive to Omnicell’s non-GAAP EBITDA first quarter of 2023 Omnicell, Inc....

Strategic acquisition of leading specialty pharmacy management services provider supports the Autonomous Pharmacy vision and expands Omnicell’s Advanced Services portfolio Addresses significant need for access to and management of complex...

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the upcoming investor conferences: Randall Lipps, Omnicell Chairman,...

Automated Controlled Substance Dispenser to accommodate Fresenius Kabi Simplist® MicroVault® Pre-filled Syringes Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and...

First Veterans Affairs facility to implement automation and technology-enabled services to support more cost-effective workflows and enhance pharmacy operations Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leading provider of...